Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some safety claims (myelosuppression, anemia, thrombocytopenia, hepatotoxicity, bone marrow suppression, infection risk with neutropenia) align with the label. However, multiple symptom-specific adverse event claims and patient-counseling “seek urgent medical attention” statements are not supported by the provided label excerpts, and there are internal citation/support determination inconsistencies.
Category Scores
Accurate Statements
Lurbinectedin (Zepzelca) can cause myelosuppression, including neutropenia and leukopenia.
Supported by 5.1 Myelosuppression.
Myelosuppression from lurbinectedin can increase infection risk.
Supported by 5.1 Myelosuppression (e.g., febrile neutropenia/sepsis and fatal infections).
Lurbinectedin can cause anemia.
Supported by 5.1 Myelosuppression.
Lurbinectedin can cause thrombocytopenia.
Supported by 5.1 Myelosuppression.
Thrombocytopenia from lurbinectedin can increase bleeding risk.
Partially supported by 5.1 Myelosuppression and 2.2 Dosage Modifications for Adverse Reactions (platelet thresholds tied to bleeding severity for dose modifications).
Lurbinectedin can cause hepatotoxicity and liver enzyme elevations.
Supported by 2.2 Dosage Modifications for Adverse Reactions (Hepatotoxicity) and 17 Patient Counseling Information (hepatotoxicity).
Lurbinectedin can suppress bone marrow activity.
Supported by 5.1 Myelosuppression and 17 Patient Counseling Information (myelosuppression).
Neutropenia from lurbinectedin increases infection risk.
Supported by 5.1 Myelosuppression.
Unsupported Statements
Anemia from lurbinectedin contributes to fatigue and weakness.
The provided label excerpts do not state a causal linkage between anemia and fatigue/weakness.
Lurbinectedin can cause fatigue.
Not supported by the provided label excerpts.
Lurbinectedin can cause nausea.
Only antiemetic prophylaxis medications are referenced; the provided excerpts do not explicitly list nausea as an adverse reaction.
Lurbinectedin can cause vomiting.
Not supported by the provided label excerpts.
Lurbinectedin can cause diarrhea.
Not supported by the provided label excerpts.
Lurbinectedin can cause constipation.
Not supported by the provided label excerpts.
Lurbinectedin can cause decreased appetite.
Not supported by the provided label excerpts.
Lurbinectedin can cause dyspnea (shortness of breath).
Not supported by the provided label excerpts.
Lurbinectedin can cause cough.
Not supported by the provided label excerpts.
Lurbinectedin can cause electrolyte abnormalities, such as low sodium or low potassium.
Not supported by the provided label excerpts.
Lurbinectedin can cause renal impairment.
Not supported by the provided label excerpts.
Renal impairment from lurbinectedin may worsen creatinine or other renal markers.
Not supported by the provided label excerpts.
Patients taking lurbinectedin are advised to seek urgent medical attention for fever or chills, especially during periods of low neutrophils.
Not supported by the provided label excerpts (no explicit fever/chills urgent-counseling language is shown).
Patients taking lurbinectedin are advised to seek urgent medical attention for shortness of breath, worsening cough, or trouble breathing.
Not supported by the provided label excerpts.
Patients taking lurbinectedin are advised to seek urgent medical attention for severe diarrhea, inability to keep fluids down, or signs of dehydration.
Not supported by the provided label excerpts.
Contradictions
Low
AI Statement
Patients taking lurbinectedin are advised to seek urgent medical attention for yellowing of the skin/eyes or dark urine, possible signs of liver issues.
Label Reference
17 PATIENT COUNSELING INFORMATION (hepatotoxicity counseling references contacting provider for signs/symptoms, but the provided excerpt does not explicitly include the specific symptom pair 'yellowing of the skin/eyes or dark urine').
Important Omissions
Specific label-based patient counseling for myelosuppression signs/symptoms is broadly referenced, but the provided excerpts do not support the precise symptom lists included in the AI claims (e.g., fever/chills for low neutrophils). A fully label-faithful counseling statement would need the exact symptoms listed in the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several adverse effect and urgent-care symptom triggers are not supported by the provided label excerpts. While some key cytopenia/myelosuppression warnings are accurate, unsupported symptom-counseling could mislead patients about when to seek urgent care.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Overextended symptom-specific adverse reaction claims and specific urgent-care counseling triggers that are not supported by the provided label sections.
Suggested Improvement
Restrict adverse reaction and patient-counseling statements to those explicitly supported in the provided label excerpts (e.g., myelosuppression/cytopenias and general instruction to contact provider for myelosuppression/hepatotoxicity signs/symptoms) and remove or rephrase unsupported symptom lists (fatigue/weakness, nausea/vomiting/diarrhea/constipation/decreased appetite, dyspnea/cough, electrolyte abnormalities, renal impairment, and fever/chills/respiratory/GI dehydration symptom triggers).